Wednesday, January 26, 2022

US tells J&J millions of vaccine doses from troubled plant can’t be used

US media reports quoting people familiar with the matter put the number at 60 million.

Other News

The US Food and Drug Administration (FDA) said Friday it had told Johnson & Johnson that millions of doses of Covid vaccine produced at a troubled plant can’t be used because of possible contamination issues.

In a statement, the FDA said “several” batches of vaccine manufactured at the Emergent BioSolutions facility in the city of Baltimore are not suitable for use. Each batch is known to correspond to several million doses.

Neither the agency nor Johnson & Johnson revealed the precise number doses, but the New York Times placed the number at 60 million, quoting people familiar with the matter.

“These actions followed an extensive review of records, including the production history of the facility and the testing performed to evaluate the quality of the product,” said FDA scientist Peter Marks.

The Emergent plant was ordered to pause production in April several weeks after it was determined that batches of substance used to produce the Johnson & Johnson vaccine were cross-contaminated with ingredients from the AstraZeneca vaccine, ruining a reported 15 million Johnson & Johnson doses.

The FDA is still deciding whether to allow the factory to reopen. Sixty million AstraZeneca doses produced there and earmarked to be donated abroad are currently being inspected for quality before they can be shipped.

All of the Johnson & Johnson vaccines distributed and used in the US so far were made in the Netherlands, not in Baltimore.

On the other hand, the FDA said it was green-lighting two batches of Johnson & Johnson vaccine made at the plant – that is to say, 10 million doses of the one-shot regimen, a source familiar with the matter said.

Additional Johnson & Johnson batches remain under review.

“Johnson & Johnson has committed to producing safe, high-quality vaccines in order to bring health and hope to people everywhere,” said Johnson & Johnson executive vice-president Kathy Wengel.

Follow us on Telegram for the latest updates:

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles